DES versus Tamoxifen in Advanced Breast Cancer

L. V.A.M. Beex, G. F.F.M. Pieters, A. G.H. Smals, A. J.M. Koenders, Th J. Benraad, P. W.C. Kloppenborg, Christian Jacquot, Rosalinda Graterol, Jean Bariety, Loïc Capron, Jean Noël Fiessinger, Ian Tannock, Norman Boyd, Roy Clark, Merrill I. Feldman, James N. Ingle

Research output: Contribution to journalLetter

10 Scopus citations

Abstract

To the Editor: In their article in the January 1 issue, Ingle et al.1 stated that in four of 11 patients who had tumor regression and subsequent reactivation during treatment with diethylstilbestrol (DES), withdrawal reactions were observed after discontinuation of this drug. Patients in whom DES failed and patients first treated with tamoxifen were not entered into a withdrawal phase but were subsequently treated with tamoxifen or DES. In the discussion, the authors speculate that some of the tumor regressions observed during subsequent DES treatment were in fact withdrawal responses to discontinuation of tamoxifen. In a randomized trial we compared.

Original languageEnglish (US)
Pages (from-to)1041-1043
Number of pages3
JournalNew England Journal of Medicine
Volume304
Issue number17
DOIs
StatePublished - Apr 23 1981

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'DES versus Tamoxifen in Advanced Breast Cancer'. Together they form a unique fingerprint.

  • Cite this

    Beex, L. V. A. M., Pieters, G. F. F. M., Smals, A. G. H., Koenders, A. J. M., Benraad, T. J., Kloppenborg, P. W. C., Jacquot, C., Graterol, R., Bariety, J., Capron, L., Fiessinger, J. N., Tannock, I., Boyd, N., Clark, R., Feldman, M. I., & Ingle, J. N. (1981). DES versus Tamoxifen in Advanced Breast Cancer. New England Journal of Medicine, 304(17), 1041-1043. https://doi.org/10.1056/NEJM198104233041714